CD8A and neoplasm: Moreover, results of MCP-counter, EPIC, xCell, quanTIseq, and CIBERSORT revealed that infiltrating level of CD8+ T cell was lower in high-risk group, suggesting weaker immune defense against tumor in high-risk group.